Aytu Biopharma, Inc 8-K Filing
Ticker: AYTU · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1385818
| Field | Detail |
|---|---|
| Company | Aytu Biopharma, Inc (AYTU) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Aytu Biopharma, Inc (ticker: AYTU) to the SEC on Dec 10, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ch Registered Common Stock , par value $0.0001 per share AYTU The Nasdaq Capital M).
How long is this filing?
Aytu Biopharma, Inc's 8-K filing is 2 pages with approximately 723 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 723 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2025-12-10 16:05:23
Key Financial Figures
- $0.0001 — ch Registered Common Stock , par value $0.0001 per share AYTU The Nasdaq Capital M
Filing Documents
- aytu20251204_8k.htm (8-K) — 42KB
- logo01.jpg (GRAPHIC) — 4KB
- 0001437749-25-037389.txt ( ) — 184KB
- aytu-20251210.xsd (EX-101.SCH) — 3KB
- aytu-20251210_def.xml (EX-101.DEF) — 12KB
- aytu-20251210_lab.xml (EX-101.LAB) — 15KB
- aytu-20251210_pre.xml (EX-101.PRE) — 12KB
- aytu20251204_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On December 10, 2025, Aytu BioPharma, Inc. (the "Company") held its 2026 annual meeting of stockholders ("2026 Annual Meeting"). At the close of business on October 13, 2025, the record date for the 2026 Annual Meeting, there were 10,188,208 shares of the Company's common stock issued and outstanding with each share being entitled to one vote and to be voted together as one class at the 2026 Annual Meeting. At the 2026 Annual Meeting, there were present in person or by proxy 6,083,713 shares of the Company's common stock, representing stockholders entitled to vote of approximately 60% of the total issued and outstanding on the record date and constituting a quorum. Set forth below are the voting results for the three proposals considered and voted upon at the 2026 Annual Meeting, all of which were described in the Company's Definitive Proxy Statement on Schedule 14A filed with the United States Securities and Exchange Commission on October 24, 2025: Proposal No. 1 - Election of Directors The Company's stockholders elected all of the incumbent directors that stood for reelection. Each director was elected by a majority vote. The directors elected and the final vote tabulation for each director is as follows: Director Votes Cast For Votes Withheld Broker Non-Votes Joshua R. Disbrow 3,192,818 351,123 2,539,772 John A. Donofrio, Jr. 3,269,350 274,591 2,539,772 Carl C. Dockery 3,210,190 333,751 2,539,772 Abhinav "Abi" Jain 3,455,220 88,721 2,539,772 Vivian H. Liu 3,454,342 89,599 2,539,772 Proposal No. 2 - Appointment of Independent Registered Public Accounting Firm The Company's stockholders approved the proposal to ratify the appointment by the Company's Audit Committee of Grant Thornton LLP, as the Company's independent registered public accounting firm for the fiscal year ended June 30, 2026. The final vote tabulation for this proposal is as follows: Vo
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AYTU BIOPHARMA, INC. Date: December 10, 2025 By: /s/ Ryan J. Selhorn Ryan J. Selhorn Chief Financial Officer